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Abstract: Due to practical and ethical concerns associated with human experimentation, animal models have been 
essential in cancer research. However, the average rate of successful translation from animal models to clinical 
cancer trials is less than 8%. Animal models are limited in their ability to mimic the extremely complex process of 
human carcinogenesis, physiology and progression. Therefore the safety and efficacy identified in animal studies is 
generally not translated to human trials. Animal models can serve as an important source of in vivo information, but 
alternative translational approaches have emerged that may eventually replace the link between in vitro studies and 
clinical applications. This review summarizes the current state of animal model translation to clinical practice, and 
offers some explanations for the general lack of success in this process. In addition, some alternative strategies to 
the classic in vivo approach are discussed. 
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Introduction
Prior to embarking on cancer drug trials, phar-
maceutical companies and independent inves-
tigators conduct extensive pre-clinical studies. 
In vitro (test tube or cell culture) and in vivo (ani-
mal experiments) studies examine preliminary 
efficacy, toxicity and pharmacokinetics. Early in 
vivo testing specifically aims to demonstrate 
safety, which assists investigators to determine 
whether a candidate drug has scientific merit to 
justify further development. Both the Food and 
Drug Administration (FDA) and Health Canada 
require that animal tests be conducted before 
humans are exposed to a new molecular entity 
[1, 2].
The ultimate goal of cancer researchers is to 
translate scientific findings into practical clini-
cal applications. Experimental discoveries are 
thought to begin at “the bench” with basic 
research, progress through pre-clinical animal 
studies, then show therapeutic efficacy in 
human clinical trials. Although animal models 
continue to play a large role in the evaluation of 
efficacy and safety of new cancer interventions, 
genetic, molecular, and physiological limita-
tions often hinder their utility. Despite success-
ful pre-clinical testing, 85% of early clinical tri-
als for novel drugs fail; of those that survive 
through to phase III, only half become approved 
for clinical use [3]. The largest proportion of 
these failures occurs in trials for cancer drugs 
[4]. Furthermore, fewer than one in five cancer 
clinical trials find their way to the peer-reviewed 
literature, generally due to negative findings [5]. 
Although logistical and study design issues are 
often identified as the root cause of clinical trial 
failures, most futilities in fact originate from 
molecular mechanisms of the drug(s) tested 
[6]. 
The overall result is that promising pre-clinical 
animal studies that require extensive resources 
both in time and money rarely translate into 
successful treatments. This review provides a 
critical evaluation of pre-clinical animal models 
and their role in translation to clinical practice 
for cancer patients.
Limitations of animal models in cancer re-
search
Animal models have not been validated as a 
necessary step in biomedical research in the 
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scientific literature [7]. Instead, there is a grow-
ing awareness of the limitations of animal 
research and its inability to make reliable pre-
dictions for human clinical trials [8]. Indeed, 
animal studies seem to overestimate by about 
30% the likelihood that a treatment will be 
effective because negative results are often 
unpublished [9]. Similarly, little more than a 
third of highly cited animal research is tested 
later in human trials [10]. Of the one-third that 
enter into clinical trials, as little as 8% of drugs 
pass Phase I successfully [11]. 
The major pre-clinical tools for new-agent 
screening prior to clinical testing are experi-
mental tumors grown in rodents. Although mice 
are most commonly used, they are actually 
poor models for the majority of human diseas-
es [12]. Crucial genetic, molecular, immunolog-
ic and cellular differences between humans 
and mice prevent animal models from serving 
as effective means to seek for a cancer cure 
[13]. Among 4,000+ genes in humans and 
mice, researchers found that transcription fac-
tor binding sites differed between the species 
in 41% to 89% of cases [14]. In many cases, 
mouse models serve to replicate specific pro-
cesses or sets of processes within a disease 
but not the whole spectrum of physiological 
changes that occur in humans in the disease 
setting [15]. 
The failure to translate from animals to humans 
is likely due in part to poor methodology and 
failure of the models to accurately mimic the 
human disease condition. The core of the prob-
lem may be rooted in the animal modeling 
itself. Unlike in human clinical trials, no best-
practice standards exist for animal testing [14]. 
Moreover, the laboratory environment can have 
a significant effect on experimental results, as 
stress is a common factor in caged mice [16]. It 
has been recommended that therapeutic 
agents should not only be evaluated in rodents, 
but also in higher animal species, and that ran-
domization and outcomes assessor blinding 
should be performed. In addition, experiments 
should be designed in both genders and in dif-
ferent age groups of animals and all data, both 
positive and negative, should be published [3].
Notable examples of failed clinical cancer tri-
als initiated due to successful animal models
A well-known example of a successful animal 
model that did not translate into clinical trials is 
the TGN1412 trial [17]. The drug TGN1412, 
developed by the company TeGenero, was 
described as an immunomodulatory human-
ized agonistic anti-CD28 monoclonal antibody 
developed for the treatment of immunological 
diseases such as multiple sclerosis, rheuma-
toid arthritis and certain cancers. Before con-
ducting human trials, TGN1412 was tested on 
different animals including mice, to ensure 
safety and efficacy in preclinical animal models 
[17]. These toxicity studies demonstrated that 
doses hundred times higher than that adminis-
tered to humans did not induce any toxic reac-
tions. In the first human clinical trials of 
TGN1412, the drug caused catastrophic sys-
temic organ failure in patients, despite being 
administered at a sub-clinical dose that was 
500 times lower than the dose found safe in 
animal studies [18]. 
In a recent report, a Phase II randomized clini-
cal trial of the Hedgehog pathway antagonist 
IPI-926 (saridegib) in patients with advanced 
chondrosarcoma was stopped early for futility 
[19]. The Hedgehog pathway is dysregulated in 
a variety of solid tumors and provides key 
growth and survival signals to tumor cells. 
Mutations resulting in constitutive Hedgehog 
signaling are causal in cartilage tumors such as 
chondrosarcoma [20]. The Phase II clinical trial 
for IPI-926 translated from a successful animal 
model of IPI-926 on a malignant solid brain 
tumor [21]. IPI-926 treated mice with the 
advanced brain tumors gained a fivefold 
increase in survival [21]. However, IPI-926 
showed no effect compared to placebo in the 
human trial [19]. Therefore even a targeted 
molecular approach did not result in clinical 
efficacy despite remarkable success in mice.
Matrix metalloproteinases (MMPs) are a family 
of zinc-dependent proteinases involved in the 
degradation and remodeling of extracellular 
matrix proteins and are associated with the 
tumorigenic process. MMPs promote tumor 
invasion and metastasis, regulating host 
defense mechanisms and normal cell function 
[22]. Cancer and arthritis were once regarded 
as the prime indications for the use of MMP 
inhibitors (MMPIs) and results from multiple 
animal studies indeed indicated that MMP inhi-
bition would be an effective therapeutic 
approach in the management of cancer and 
other diseases [15]. However, multiple failed 
clinical trials in humans have had the effect of 
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seriously reducing interest in MMP inhibition as 
a valid therapeutic option [22].
Among the more-than 16 MMPIs that pro-
gressed to clinical testing, only Periostat (doxy-
cycline hyclate, a nonspecific MMPI) has been 
approved for clinical use in periodontal disease 
[15]. The serious safety problems in clinical tri-
als have been attributed to poor selectivity of 
the MMPIs, poor target validation for the tar-
geted therapy and poorly defined predictive 
preclinical animal models for safety and effica-
cy [23]. The failure and indeed resulting dam-
age of all anti-MMP drugs in clinical trials indi-
cated that MMPs as a class have useful 
functions in normal tissue, and therefore inhibi-
tion would result in toxicities in the human host 
not identified in the animal models in which 
they were tested. 
Therapeutic cancer vaccines are becoming 
increasingly popular in the approach to cancer 
treatment. The concept of stimulating the 
body’s immune system to fight tumors, repre-
senting an alternative approach to the use of 
traditional cytotoxic cancer therapies, is indeed 
compelling [24]. A typical therapeutic vaccine 
against cancer contains a cancer-specific pep-
tide, or protein fragment, that is injected under 
the skin of either the tested animals or humans. 
It is assumed that the immune system would 
recognize the peptide as something to be 
attacked and boosts the population of cancer-
fighting T-cells in the bloodstream [25]. These 
vaccines must first be tested in animals to con-
firm efficacy prior to entering into human clini-
cal trials [26]. In the particular case of cancer, 
preclinical animal models have provided new 
knowledge regarding vaccine-induced immune 
responses and the central importance of T cell-
mediated cellular responses in cancer treat-
ment [25].
Although therapeutic cancer vaccines have 
been effective in initiating the immune 
response in animal models, they have pro-
duced mixed results in human clinical trials. In 
a recent review article, it was reported that out 
of 23 Phase II/III clinical trials testing 17 dis-
tinct therapeutic anticancer vaccines, 18 of 
these studies had failed [27]. Some examples 
are Merck’s Stimuvax (failed a phase III trial on 
non-small cell lung cancer) [28], Glaxo- 
SmithKline’s MAGE-A3 (failed a phase III mela-
noma trial) [29], Vical’s Allovectin (failed a 
phase III metastatic melanoma trial) [30], and 
KAEL-GemVax’s TeloVac (failed a phase III pan-
creatic cancer trial) [31]. It has been postulated 
that most of the cancer vaccine trials have 
failed due to elevated levels of circulating 
immunosuppressive cytokines and various 
immunological checkpoints in humans that 
may not be present in rodents [25]. 
Critical re-evaluation of animal models and 
alternative strategies
Despite the general lack of success in translat-
ing animal models to clinical studies, animals 
are still prevalently used in laboratories all over 
the world to test the safety, toxicity and effec-
tiveness of drugs [32]. Animal models have 
been essential in cancer research for obvious 
practical and ethical concerns associated with 
human experimentation. Animal research is 
similar to in vitro assays, epidemiological inves-
tigations, and computer simulations. All 
attempt to derive probabilistic knowledge in 
one context that will generalize to humans. All 
are forms of modeling that will map onto the 
whole population with less than perfect preci-
sion and predict with even less precision the 
fate of any individual. Notwithstanding, these 
methods risk missing some important knowl-
edge, or risk finding knowledge that doesn’t 
hold up in the clinical setting even to a point 
that is actually harmful once widely deployed. 
Ultimately, we come into the question as to 
whether we should spare resources and bypass 
animal models to evaluate therapy in humans 
directly. In the last decade, the FDA and the 
European Medicines Agency introduced guide-
lines for testing very small ‘micro-doses’ of 
drugs in humans [33]. These are concentra-
tions less than a one-hundredth of the thera-
peutic dose. Because the concentrations are 
so low, the drugs can be tested in a small num-
ber of patients without the level of safety data 
normally required before a phase I study. These 
early ‘phase 0’ studies collect human data 
quickly by showing how the drug is distributed 
and metabolized in the body, and whether it 
hits the right molecular target. Approximately 
one-quarter of the molecules entering clinical 
trials fail due to pharmacological issues such 
as lack of absorption or penetration into the 
target organ [33]. With a direct test in humans, 
pharmaceuticals can determine earlier wheth-
er the drug is worth investing both time and 
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money into clinical research. Phase 0 trials may 
be small in scope, but they require very sensi-
tive tests to detect the minute quantities of the 
drug in the body and possibly its mechanism of 
action.
Aside from phase 0 studies, a wide range of 
alternatives to animal-based preclinical 
research has emerged. These include epidemi-
ological studies, autopsies, in vitro studies, in 
silico computer modelling, “human organs on a 
chip” - creating living systems on chips by mim-
icking a micro- biological environment with cells 
of a certain organ implanted onto silicon and 
plastic chips [34], and “microfluidic chips” - 
automation of over a hundred cell cultures or 
other experiments on a tiny rubbery silicone 
integrated circuit with miniscule plumbing [35]. 
The National Institutes of Health of the United 
States suspended all new grants for biomedical 
and behavioural research on chimpanzees 
after an expert committee concluded that such 
research was unnecessary [36]. Furthermore, 
the US National Research Council recommends 
that animal model based tests be replaced as 
soon as possible with in vitro human cell-based 
assays, in silico models, and an increased 
emphasis on epidemiology [37]. 
In summary, animal models have been the 
basic translational model in the preclinical set-
ting in elucidating key biochemical and physio-
logic processes of cancer onset and propaga-
tion in a living organism. Experimental tumors 
raised in animals, particularly in rodents, con-
stitute the major preclinical tool of evaluating 
novel diagnostic and therapeutic anticancer 
drugs screening before clinical testing. The 
power of the animal models to predict clinical 
efficacy is a matter of dispute due to weakness-
es in faithfully mirroring the extremely complex 
process of human carcinogenesis. The vast 
majority of agents that are found to be success-
ful in animal models do not pan out in human 
trials. Differences in physiology, as well as vari-
ations in the homology of molecular targets 
between mice and humans, may lead to trans-
lational limitations. Even though animal models 
still remain a unique source of in vivo informa-
tion, other emerging translational alternatives 
may eventually replace the link between in vitro 
studies and clinical applications. 
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